Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 6/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956747 | 0.98 | LTA4H (0.51) | TSHRLTA4HTDP1POLB | |
| SCHEMBL3583393 | 0.92 | HRH3 (0.54) | KDM4ESMN1; SMN2HRH1 | |
| SCHEMBL8623642 | 0.90 | ALDH1A1 (0.55) | KDM4ESMN1; SMN2HRH1DRD2DRD1 | |
| SCHEMBL2182155 | 0.86 | LTA4H (0.51) | LTA4HTDP1POLBKDM4EDRD3 | |
| SCHEMBL826085 | 0.84 | NPC1 (0.54) | LTA4HPOLBKDM4EDRD1DRD4 | |
| SCHEMBL5656583 | 0.83 | ESR1 (0.37) | TSHRLTA4HKDM4ESMN1; SMN2HRH1 | |
| SCHEMBL3960266 | 0.81 | ALDH1A1 (0.37) | TSHRLTA4HTDP1POLBKDM4E | |
| SCHEMBL2183678 | 0.79 | NOS3 (0.47) | KDM4ESMN1; SMN2DRD2 | |
| SCHEMBL6292255 | 0.78 | HRH3 (0.54) | LTA4HPOLBKDM4EHRH1DRD2 | |
| SCHEMBL2180630 | 0.78 | LTA4H (0.55) | LTA4HKDM4ESMN1; SMN2HRH1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | claimed |
| US-5731342-A | FOR TREATING AND PREVENTING POSTMENOPAUSAL SYNDROME AND BREAST CANCER | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | claimed |
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20220409552-A1 | FORMULATIONS OF TERAMEPROCOL AND TEMOZOLOMIDE AND THEIR USE IN STIMULATION OF HUMORAL IMMUNITY IN TUMORS | NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) | 2022-12-29 | — | — | US | disclosed |
| WO-2021108601-A1 | FORMULATIONS OF TERAMEPROCOL AND TEMOZOLOMIDE AND THEIR USE IN STIMULATION OF HUMORAL IMMUNITY IN TUMORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20190111040-A1 | IN VIVO AMELIORATION OF ENDOGENOUS ANTI-TUMOR AUTOANTIBODIES TARGETING SURFACE TUMOR ANTIGENS VIA LOW-DOSE P4N | UNIV JOHNS HOPKINS (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3436008-A1 | IN VIVO AMELIORATION OF ENDOGENOUS ANTI-TUMOR AUTOANTIBODIES TARGETING SURFACE TUMOR ANTIGENS VIA LOW-DOSE P4N | The Johns Hopkins University (US) | 2019-02-06 | — | — | EP | disclosed |
| WO-2017173022-A1 | IN VIVO AMELIORATION OF ENDOGENOUS ANTI-TUMOR AUTOANTIBODIES TARGETING SURFACE TUMOR ANTIGENS VIA LOW-DOSE P4N | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | disclosed |
| EP-1102755-B1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-6869969-B2 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6743815-B2 | OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | CHIRON CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-20030065012-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2003-04-03 | — | — | US | disclosed |
| US-6387920-B2 | ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2002-05-14 | — | — | US | disclosed |
| US-20010036956-A1 | Estrogen receptor modulators | HUEBNER VERENA D (US) | 2001-11-01 | — | — | US | disclosed |
| US-6262098-B1 | ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-5886025-A | METHOXY AND ETHOXY SUBSTITUTED 3-AROYL-2-ARYLBENZO(B)THIOPHENES AND BENZO(B)THIOPHENE ANALOGUES | BAYLOR UNIVERSITY (US) | 1999-03-23 | — | — | US | disclosed |
| US-5856341-A | INHIBITING BONE LOSS OR BONE RESORPTION, PARTICULARLY OSTEOPOROSIS, CARDIOVASCULAR-RELATED PATHOLOGICAL CONDITIONS INCLUDING HYPERLIPIDEMIA, ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| US-5798351-A | USEFUL FOR INHIBITING BONE LOSS, LOWERING SEUM CHOLESTEROL LEVELS AND TREATING HORMONE DEPENDENT MAMMALIAN BREAST AND UTERINE CANCER | ELI LILLY AND COMPANY (US) | 1998-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036956-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | TSHR 247/4885LTA4H 886/4885TDP1 3767/4885 |
| US-20190111040-A1 | IN VIVO AMELIORATION OF ENDOGENOUS ANTI-TUMOR AUTOANTIBODIES TARGETING SURFACE TUMOR ANTIGENS VIA LOW-DOSE P4N | ATP5F1A, SLC25A6, FCGRT | TSHR 3211/4885LTA4H 1668/4885TDP1 3336/4885 |
| US-20220409552-A1 | FORMULATIONS OF TERAMEPROCOL AND TEMOZOLOMIDE AND THEIR USE IN STIMULATION OF HUMORAL IMMUNITY IN TUMORS | PTGES, MYD88, GMFG | TSHR 910/4885LTA4H 683/4885TDP1 1886/4885 |
| US-20030065012-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | TSHR 247/4885LTA4H 886/4885TDP1 3767/4885 |
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TCF4, TCF7L2, CTNNB1 | TSHR 4571/4885LTA4H 3758/4885TDP1 3665/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | TSHR 2089/4885LTA4H 2556/4885TDP1 941/4885 |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | ESR2, GPER1, ESR1 | TSHR 557/4885LTA4H 1094/4885TDP1 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.